Abstract BACKGROUND: Analysis of the H-CUP database shows that in the US 3.86 million ED visits were from patients with a primary diagnosis of Acute Bacterial Skin and Skin Structure Infections (ABSSSI), leading to ~700K admissions. Analyses of hospital claims indicate 74% of ABSSSI admissions involve empiric treatment with methicillin-resistant Staphylococcus aureus (MRSA)-active antibiotics. Hospitalization costs could be reduced if moderate-severe ABSSSI patients were treated to a greater extent in outpatient setting, including use of observation. Oritavancin is indicated as a single, once-only 1200 mg IV dose for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of designated gram-positive bacteria, including MRSA. The aim of our analysis was to quantify the economic value of using oritavancin for ABSSSI patients at risk of MRSA from a US hospital perspective. METHODS: A decision analytic model based on current clinical practice was developed to estimate the economic value of decreased hospital resources by using oritavancin. Utilization of antibiotics was informed by analysis of the Premier hospital database. Demographic and clinical data were derived from the literature. Observation, laboratory, administration costs were based on Medicare National Limitation amounts. Drug costs were 2014 wholesale acquisition costs. RESULTS: For a hypothetical US hospital treating 1,000 ABSSSI patients per year eligible for IV MRSA antibiotics, use of oritavancin instead of vancomycin in moderate-severe ABSSSI (25.75% of all ABSSSI patients) facilitates shifting patients to the observation/outpatient setting with a total annual cost savings of $1.40 MM. CONCLUSIONS: Using oritavancin instead of vancomycin in moderate-severe ABSSSI patients, including those at risk of MRSA, is estimated to deliver an estimated cost reduction of $1,398/patient by shifting patient care to the observation/outpatient setting and decreasing resource utilization.
Background
• Analysis of the H-CUP database shows that in the US, 3.86 million ED visits were from patients with a primary diagnosis of ABSSSI, leading to ~700K admissions. 1 • Outpatient treatment, including use of observation units, may be utilized to avoid hospitalization and to reduce inpatient length of stay (LOS) and associated hospital costs. 2, 3 • Oritavancin is indicated as a single, once-only 1200 mg IV dose for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of designated gram-positive bacteria, including MRSA.
• The aim of our analysis was to evaluate the economic value of using oritavancin for moderate-to-severe (Eron class II and III) ABSSSI patients at risk of MRSA from a hospital perspective. o The model allows an individual US hospital to estimate the budget impact of using oritavancin in both the inpatient and outpatient setting. o Eron is a clinical consensus algorithm that categorizes ABSSSI infections into four classes of ascending severity and recommends appropriate treatment settings -the target patient for oritavancin most closely aligns to Eron class II and III (moderatesevere) patients. 4  Patients within these classes are characterized by an ill or toxic appearance with few or no comorbidities and do not exhibit sepsis syndrome or a life-threatening infection.  An analysis of the Premier hospital database using criteria adapted from the Eron classification indicates that class II and III patients comprise 25.75% of the ABSSSI population who are discharged from the ED or inpatient setting. 5
Methods
• A decision analytic model based on current clinical practice was developed to simulate treatment of ABSSSI patients with suspected or confirmed MRSA. (Figure 1 ) • The perspective of the model is from a US hospital whose patients currently return to a hospital-owned setting for outpatient treatment (e.g., a hospital-owned ambulatory infusion center) • The model simulates a cohort of 1,000 ABSSSI patients eligible for MRSA-active antibiotics per year and costs include the index treatment episode and 30-day rehospitalization.
• Clinical inputs were derived from a literature search and a network meta-analysis (NMA).
( Table 1) • The reimbursement associated with current procedural terminology (CPT) codes based on Medicare National Limitation amounts were used as proxy for the cost for observation care, laboratory and drug administration costs.
• Health resources were informed by published sources and expert opinion. (Table 2) • Drug costs were based on 2014 wholesale acquisition costs. 6 (Table 3) • All costs were inflated to 2014 values using the medical Consumer Price Index (CPI). 7 • The base case reflects the national average usage of MRSA-active antibiotics. (Table 1) • In the scenario case, oritavancin was assumed to be used in 25.75% of patients, representing moderate-to-severe ABSSSI (Eron class II and III). o Oritavancin was assumed to be used in 5% inpatient, 15% ED/outpatient, and 80% observational setting. o Oritavancin usage displaced vancomycin from the base case to scenario case, and all other antibiotic use was unchanged.
Results
• In shifting patients from the base case to the scenario treatment involving oritavancin, less patients were treated as inpatients and observation unit use increased.
• The budget impact model results indicate that, in a cohort of 1,000 ABSSSI patients eligible for IV MRSA antibiotics/year, using oritavancin in moderate-severe ABSSSI (25.75% of patients) instead of vancomycin translates to a total cost savings of 13. 
Conclusions
• Oritavancin may reduce total hospital costs when used instead of vancomycin for the treatment of moderate-severe ABSSSI in a predominantly outpatient/observational setting. o Inpatient cost savings were derived from a reduction in hospitalizations. o Observation costs increased slightly with greater use of observation units. o Outpatient costs decreased due to lower drug administration burden.
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